Ind-Swift Laboratories is a pharmaceutical company that has just completed a radical reinvention. For nearly three decades, it was one of India’s largest independent manufacturers of Active Pharmaceutical Ingredients (APIs)-the chemical building blocks of medicines-supplying over 70 countries. In 2024, it sold that entire business to become debt-free and simultaneously merged with a group company to transform itself into a pure-play maker of finished tablets, capsules, and syrups, a business built on the same global customer relationships but now focused on the final product patients receive.
Business segments
A single engine with two complementary cylinders-a high-growth export unit that makes medicines for global generic giants, and a domestic unit that provides steady cash flow by selling branded drugs to Indian doctors and retailers.
1. Global finished-dosage manufacturing: the export engine
The company makes tablets, capsules, and sachets under long-term contracts for some of the world’s largest generic drug companies, earning revenue through manufacturing fees, out-licensing of its own product dossiers, and direct sales of its own brands in select emerging markets.
- Paid to manufacture for giants - it runs sticky, multi-year contract manufacturing relationships averaging 9-10+ years with companies like Viatris, Mylan, Teva, and Wockhardt, producing high-volume medicines at its export-only facility in Derabassi, Punjab.
- The dossier library is the moat - it has filed over 1,915 product dossiers with regulators globally and secured more than 520 approvals, a portfolio of intellectual property that creates a pipeline of future manufacturing contracts and out-licensing deals.
- Complex products, higher barriers - the company is pivoting toward complex generics and controlled substances, such as ADHD molecules, and has patented its own novel salt, Clarithromycin Citrate, in the US, Europe, and India, giving it exclusive manufacturing rights on a differentiated product.
- Own brands in untapped markets - in regions like the GCC, Uzbekistan, and East Africa, it bypasses partners and markets directly under its own brand names using a field force of 125+ medical representatives, capturing the full marketing margin instead of just a manufacturing fee.
2. Domestic branded formulations: the stability engine
The company sells branded prescription drugs directly to Indian doctors and also manufactures for other Indian pharma companies, generating consistent cash flow with higher gross margins than the export business.
- Prescriptions drive the core - its Ethical Division deploys over 260 marketing staff to detail products to more than 25,000 doctors, focusing on high-margin therapies in gynecology and pediatrics, a business that generates 76% gross margins.
- Made for India’s own pharma companies - the P2P division is a contract manufacturer for leading Indian firms including Cipla, Lupin, Mankind, and Concord, with 39 active, repeat clients who place orders for tablets and capsules made at the Samba facility in Jammu.
- A network of stockists for generics - the Generic Division distributes a portfolio of more than 700 trade-generic products through a network of 2,400 stockists and 8 carrying-and-forwarding agents, reaching retailers across India.
- Zero-credit-risk custom manufacturing - a separate vertical called Q-DEN/NOVA produces multi-specialty medicines to customer specifications on an advance-payment model, eliminating credit risk entirely.
Formulation R&D: the innovation backbone
A government-approved lab with over 60 scientists develops the complex generics, novel drug delivery systems, and regulatory dossiers that feed both the export and domestic engines.
- Dossier factory - the R&D centre in Panchkula prepares dossiers in CTD/eCTD format for the UK, EU, Australia, and Canada, creating the regulatory paperwork that makes product approvals and technology transfers possible.
- Complex formulation know-how - the team has developed gastro-resistant, delayed-release, and multiple-unit pellet system (MUPS) formulations, and is now building capabilities in injectables and topical products, expanding the range of products the company can offer.
- Pipeline for the future - over 30 non-infringing generic products are under development for regulated markets, and more than 15 products were successfully developed with completed bioequivalence studies in FY24-25 alone.
Group structure and partners
The company is the listed parent of a streamlined group, with a historic stake in its former API business and a new Dubai subsidiary aimed at future expansion.
- A stake in its own past - when it sold the API and CRAMS business to Synthimed Labs (backed by Piramal Enterprises and Bain Capital) for an enterprise value of ₹1,650 Crores, it retained a 7.80% equity stake in the buyer, keeping a financial link to the business it was built on.
- The merger that completed the reset - group company Ind-Swift Limited, which had been in the formulations business since 1986, was amalgamated into the listed entity in August 2025, bringing its domestic brands and manufacturing facilities under one roof.
- International subsidiaries - the company has a wholly-owned US subsidiary that generated sales of ₹23.76 Crores, and a Dubai subsidiary incorporated in May 2024 to explore pharmaceutical investments, acquisitions, and potential manufacturing in the Middle East.
- A joint venture for adjacent segments - it holds a 50% stake in Indis Healthcare LLP, a partnership formed in 2022 to target pharma segments where the company itself did not have a presence.